Korro Bio Q2 2026: $137.9M Cash, KRRO-121 Trial on Track for 2H 2026, Venrock Share Exchange
KRRO has more than doubled off its 52-week low of $5.204.
Summary
Korro Bio's Q2 2026 filing shows $137.9M in cash, a runway into 2H 2028, and KRRO-121 on track for a first-in-human trial in 2H 2026. A Venrock share exchange reduces outstanding shares by 1M.
Key Events · Earnings and Guidance · KRRO
-
Cash Runway Extended into 2H 2028
Cash, cash equivalents, and marketable securities totaled $137.9 million as of June 30, 2026, funding operations into the second half of 2028.
-
KRRO-121 on Track for 1H 2026 Trial
Lead candidate KRRO-121 received EMA orphan drug designation for urea cycle disorders and remains on schedule for a first-in-human trial in the second half of 2026.
-
Venrock Share Exchange Reduces Outstanding Shares
On August 5, 2026, Venrock surrendered 1 million common shares in exchange for pre-funded warrants, reducing outstanding shares to 14.7 million without immediate dilution.
-
Novo Nordisk Collaboration Pause Continues
The 12-month hold on the Novo Nordisk collaboration, effective November 2025, resulted in zero collaboration revenue in Q2 2026.
Analysis · KRRO · Life Sciences
Korro Bio's Q2 2026 filing reveals a strengthened balance sheet with $137.9 million in cash and marketable securities, extending the runway into the second half of 2028. The lead program, KRRO-121, received EMA orphan drug designation and remains on track for a first-in-human trial in the second half of 2026. In a subsequent share exchange, Venrock surrendered 1 million shares for pre-funded warrants, reducing outstanding shares without immediate dilution. Meanwhile, the Novo Nordisk collaboration remains paused, contributing no revenue. These updates sharpen the picture of the company's financial health and near-term clinical catalysts.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KRRO was trading at $11.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $165.9M. The 52-week trading range was $5.20 to $55.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.